 Thank you for the opportunity to talk briefly about our work on COVID-19 at our Texas Medical Center, Baylor College of Medicine and Texas Children's. We're taking on COVID-19 on multiple aspects, including its role as a health disparity. But one of our big contributions is for vaccine development. Our Center for Vaccine Development for the last 20 years has focused on low-cost global health vaccines, especially for parasitic infections, such as Chagas disease, leishmaniasis, and schistosomiasis. But now we've also had over the last 10 years a coronavirus vaccine program in collaboration with the New York Blood Center, where we have focused on recombinant protein vaccines that include the receptor binding domain of the spike protein for SARS-1 that emerged in 2003 with a virus coronavirus. And now for this year, we've been producing the receptor binding domain of the COVID-19 virus, the SARS coronavirus type 2. So once we obtain the sequence from Chinese scientists who are putting up the sequences in bioarchive in January, we move pretty quickly to produce the SARS-2 coronavirus receptor binding domain in Pichia pastoris, a method of utilizing yeast. And we picked that for two reasons. One, our experience with SARS and mayors found that when we use this yeast receptor binding domain, we can induce high levels of virus neutralizing the antibody and without the isynophilic immune enhancement that was seen with full length spike proteins or vector virus vaccines in our laboratory animal construct. So the receptor binding domain approach was focused primarily because it appeared to remove any type of immune enhancing epitopes. And that was proved to be very successful for our COVID-19 approach. The other reason we like it is because by using yeast-derived system, this is the same approach used to make the recombinant hepatitis B vaccine that's made locally in Brazil and Cuba and Indonesia and India, Bangladesh and other countries. So the hope would be that as a receptor binding domain vaccine, it would be a low cost global health vaccine. So we prepared it. We showed that an induced virus neutralizing antibodies in a mouse system and then a non-human primate system. And now we've licensed this technology to Biological E Bio E in Hyderabad, India, one of India's big vaccine producers. And now they're scaling up to produce one billion doses of the vaccine. So this is quite exciting for us because we think it'll provide a low cost alternative for some of the other COVID-19 vaccines that seems to be inducing very high levels of virus neutralizing antibody T-cell responses, potentially is an alum formulation in combination with other immunostimulants, including potentially CPGs to give a balanced immune response. And so far, this has gone really well. And we're worried. We're worried about access of COVID-19 vaccines to low and middle-income countries in Latin America and Africa and South Asia. And we think having a low cost recombinant protein vaccine that uses the same technology as hepatitis B vaccine that could be made for a dollar or less per dose offers a lot of promise to solve this huge issue around global access for COVID-19 vaccines. So thank you for the opportunity to talk and congratulations on your conference. I look forward to speaking with you more. Some other time, I'd love to come back and discuss the other big issue that we're combating, which is this huge anti-vaccine movement that I've been involved in fighting for many years. And unfortunately, we have now our US anti-vaccine movement now expanding into Europe and to Germany, France, and the UK. And would love to discuss with you about issues about how to solve that problem as well. So thank you so much.